[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563718":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":57,"collaborators":18,"id":60,"slug":18,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":18,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":42,"whyStopped":18,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Jinling Hospital, China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Hyperbaric Oxygen Therapy","EXPERIMENTAL","Participants receive 20 session of hyperbaric oxygen therapy (HBOT) in 1 month (inhalation of 100% oxygen in a pressure chamber under 2.0 ATA for 60 minutes).",[13],"Procedure: Hyperbaric oxygen therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Symptomatic Treatment","NO_INTERVENTION","Participants receive basic symptomatic treatments like antidiabetic drug, antihypertensive drug, and hepatic protector.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"PROCEDURE","Hyperbaric oxygen therapy","Participants receive 20 session of hyperbaric oxygen therapy (HBOT) in one month (inhalation of 100% oxygen in a pressure chamber under 2.0 ATA for 60 minutes).",[9],[26],{"name":27,"affiliation":28,"role":29},"Miaofang Yang, MD","General Hospital of Eastern Theater Command, China","STUDY_DIRECTOR",[31,37],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Lu Chen, MS","CONTACT","800-555-5555","86-18690113660","522023350160@smail.nju.edu.cn",{"name":27,"role":33,"phone":18,"phoneExt":18,"email":38},"doctor_yangmf@126.com",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"General Hospital of Eastern Theater Command","RECRUITING","Nanjing","Jiangsu","210000","China",{"type":48,"coordinates":49},"Point",[50,51],118.77778,32.06167,{"lat":51,"lon":50},[54],{"name":55,"role":33,"phone":56,"phoneExt":18,"email":36},"Lu Chen","18690113660",{"type":58,"investigatorFullName":55,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","MS","100563718",false,"NCT06619808","Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases","Efficacy and Safety of Hyperbaric Oxygen Therapy in Adult Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD) Patients : a Randomized Controlled Trial","MASLD","Inclusion Criteria:\n\n* Metabolic dysfunction-associated steatotic liver disease patients\n\nExclusion Criteria:\n\n* Participants are unfit for hyperbaric treatment.\n* Participants with prior oxygen therapy within the last 6 months.\n* Participants with history of viral hepatitis, hemochromatosis, Wilson disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction, alpha-1 antitrypsin deficiency.\n* Participants with severe organ dysfunctions or malignant tumors.\n* Participants have weight loss plan or major operations within the last 6 months.\n* Participants are unable to provide informed consent or currently participating in or has within the last 3 months participated in any other clinical trial.\n* Participants are pregnant or lactating.\n* Participants with claustrophobia or that cannot decompress properly.","ALL","18 Years","75 Years",{"count":71,"type":72},150,"ESTIMATED","INTERVENTIONAL",[75],"NA","The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main questions it aims to answer are:\n\nDoes HBOT decreases the fat content and fibrosis state of liver in adult MASLD patients? Does HBOT improves the liver function and metabolic condition in adult MASLD patients?\n\nParticipants will:\n\nReceive HBOT for 20 times in 1 month or recerive regular drug; Visit the clinic for checkups and tests at the starting, ending of the therapy and 6 month after the therapy.",[78,79,80],"Metabolic Dysfunction-associated Steatotic Liver Disease","Hepatic Steatosis","Non-alcoholic Fatty Liver Diseases",[78,9,80,82],"Oxygen Therapy","2024-09-28",{"date":85,"type":86},"2024-10-01","ACTUAL",{"date":88,"type":86},"2024-07-29",{"date":90,"type":72},"2026-08-31",{"name":5,"class":6},1]